As of 2025-05-13, the Intrinsic Value of Telix Pharmaceuticals Ltd (TLX.AX) is 3.43 AUD. This TLX.AX valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 24.47 AUD, the upside of Telix Pharmaceuticals Ltd is -86.00%.
The range of the Intrinsic Value is 2.55 - 5.45 AUD
Based on its market price of 24.47 AUD and our intrinsic valuation, Telix Pharmaceuticals Ltd (TLX.AX) is overvalued by 86.00%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | 2.55 - 5.45 | 3.43 | -86.0% |
| DCF (Growth 10y) | 7.43 - 17.42 | 10.45 | -57.3% |
| DCF (EBITDA 5y) | 5.13 - 24.83 | 6.25 | -74.4% |
| DCF (EBITDA 10y) | 9.87 - 48.24 | 12.51 | -48.9% |
| Fair Value | 3.69 - 3.69 | 3.69 | -84.91% |
| P/E | 1.86 - 10.24 | 4.39 | -82.0% |
| EV/EBITDA | 1.59 - 6.95 | 2.19 | -91.0% |
| EPV | 0.57 - 0.63 | 0.60 | -97.6% |
| DDM - Stable | 1.14 - 3.25 | 2.20 | -91.0% |
| DDM - Multi | 4.98 - 11.39 | 6.98 | -71.5% |
| Market Cap (mil) | 8,267.92 |
| Beta | 1.42 |
| Outstanding shares (mil) | 337.88 |
| Enterprise Value (mil) | 8,139.03 |
| Market risk premium | 5.10% |
| Cost of Equity | 10.58% |
| Cost of Debt | 5.50% |
| WACC | 10.25% |